2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO, CA
Brenda Cooperstone Resigns from Senti Biosciences Board
Senti Biosciences Holdings, Inc. Issues $2 Million in Convertible Notes
Material disclosure
Annual Report to Security Holders
Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial TM Technology Platform
Senti Holdings Issues $10 Million in Senior Secured Convertible Notes
Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Notice of Suspension of Duty to File Reports
PRER14A
Definitive Merger Proxy Statement
Additional Proxy Materials
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
PREM14A
S-8 POS
Post-Effective Amendment to Registration Statement